Hims & Hers shares surge after reports of a Wegovy partnership with Novo Nordisk, highlighting telehealth’s growing role in the booming obesity drug market.
A key FDA vaccine official is leaving the agency, raising questions about regulatory leadership, vaccine oversight, and the ...
China approves Pfizer’s GLP-1 weight-loss drug, expanding competition in the booming obesity treatment market and highlighting rising metabolic health concerns.
Gene Therapy Meets Regulatory Reality: The FDA–uniQure Clash Over a Promising Huntington’s Treatment
The FDA’s dispute with biotech firm uniQure over Huntington’s gene therapy highlights growing tensions between innovation, ...
Bayer’s $7.25B Roundup settlement gains initial approval in Missouri, potentially resolving thousands of cancer lawsuits tied to glyphosate exposure.
Balcony solar systems are quietly transforming clean energy access. Discover how plug-in solar works, its legal challenges, ...
A new U.S. autism research panel is examining potential causes of autism, sparking debate over science, policy, and the ...
Major talcum powder verdicts are reshaping corporate liability, public health debates, and mass tort litigation nationwide.
CDC faces leadership exodus amid policy disputes, raising concerns over scientific independence and outbreak readiness.
A Single Shot to Shield Against Two Viruses: EMA Poised to Approve Moderna’s COVID-Flu Combo Vaccine
EMA backs Moderna’s dual COVID-19 and flu vaccine, mCombriax, paving the way for EU approval ahead of the 2026–2027 season.
Novo Nordisk slashes U.S. prices for Ozempic and Wegovy by up to 50%, reshaping access to diabetes and weight-loss care.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results